11 June 2020: ReNeuron Group’s (LON:RENE) Michael Hunt pitches the company to investors at the Proactive One2One Virtual Event. The company’s a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

To view the link please CLICK HERE.